The new FIT solution aims to automate processes, improve decision-making and boost efficiency in clinical development

Consalud.es

Fortrea has announced the launch of Fortrea Intelligent Technology (FIT), a suite of AI-powered tools designed to transform clinical trial management by automating processes and improving operational efficiency.

The North Carolina-based company unveiled the platform on 7 April with the aim of making trials more agile, predictable and data-driven. FIT is designed for use throughout the entire clinical development cycle, from early pharmacology to late-stage trials and medical device development.

Among its key capabilities, the platform enables the automation of workflows, real-time trend analysis and risk mitigation, facilitating more informed decision-making by sponsors and research teams. It also incorporates artificial intelligence agents that optimise the monitoring of trials and enhance collaboration between the various stakeholders involved.

The platform enables the automation of workflows, the analysis of trends in real time and the mitigation of risks

The company’s Chief Information Officer, Alejandro Martínez Galindo, emphasised that this initiative responds to the growing convergence between clinical research and artificial intelligence. As he explained, FIT offers user-centred solutions that enable trials to be conducted more efficiently, reducing uncertainty and operational risk.

Fortrea’s commitment to digitalisation comes at a time of transformation for the clinical research sector, where the complexity of trials and the pressure to accelerate the development of new treatments are driving the adoption of advanced technologies.

Since its spin-off from Labcorp in 2023, Fortrea has established a strong global presence, participating in projects across more than 20 therapeutic areas and operating in over 100 countries. The company works with both major pharmaceutical firms and emerging biotech companies to provide comprehensive clinical trial management services.

Fortrea has established a global presence, participating in projects across more than 20 therapeutic areas and operating in over 100 countries

The launch of FIT also follows a period of internal changes. In 2025, the company appointed Anshual Thakral as its new chief executive, following the departure of its founder, Thomar Pike, against a backdrop of falling share prices.

With this new platform, Fortrea aims to strengthen its position as a technology partner in clinical research, leveraging artificial intelligence as a key driver to improve productivity, reduce costs and accelerate the time-to-market for new therapies.